StockMacro
Menu

Kymera Therapeutics

$115.31 +43% in 6 monthsMarket cap $9.8B

KYMR on XNAS, Health Care, Kymera Therapeutics, Inc., job postings

Measures activity, not value. Not investment advice.

Revenue rose 134% to $102.2M, but the company lost $349.4M over 12 months.

  • BadFree cash outflow $288.9M over 12 months, against $971.2M cash

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

Industry
Biological products, (no diagnostic substances) (Health Care)
Employees
285
Website
kymeratx.com
Listed
Nasdaq, US
Last results
29 Oct 2026
Next results
expected around 12 Jan 2027 (an estimate: a year ago it reported on 13 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $0, net loss $132.0M.
Quarter to 31 Dec 2021: revenue $15.3M, net income -$33.9MQuarter to 31 Dec 2021: revenue $15.3M, net income -$33.9MQuarter to 31 Mar 2022: revenue $9.6M, net income -$36.7MQuarter to 31 Mar 2022: revenue $9.6M, net income -$36.7MQuarter to 30 Jun 2022: revenue $11.5M, net income -$40.3MQuarter to 30 Jun 2022: revenue $11.5M, net income -$40.3MQuarter to 30 Sep 2022: revenue $9.6M, net income -$43.0MQuarter to 30 Sep 2022: revenue $9.6M, net income -$43.0MQuarter to 31 Dec 2022: revenue $16.1M, net income -$34.9MQuarter to 31 Dec 2022: revenue $16.1M, net income -$34.9MQuarter to 31 Mar 2023: revenue $9.5M, net income -$40.9MQuarter to 31 Mar 2023: revenue $9.5M, net income -$40.9MQuarter to 30 Jun 2023: revenue $16.5M, net income -$38.8MQuarter to 30 Jun 2023: revenue $16.5M, net income -$38.8MQuarter to 30 Sep 2023: revenue $4.7M, net income -$52.9MQuarter to 30 Sep 2023: revenue $4.7M, net income -$52.9MQuarter to 31 Dec 2023: revenue –, net income -$14.4MQuarter to 31 Mar 2024: revenue $10.3M, net income -$48.6MQuarter to 31 Mar 2024: revenue $10.3M, net income -$48.6MQuarter to 30 Jun 2024: revenue $25.6M, net income -$42.1MQuarter to 30 Jun 2024: revenue $25.6M, net income -$42.1MQuarter to 30 Sep 2024: revenue $3.7M, net income -$62.5MQuarter to 30 Sep 2024: revenue $3.7M, net income -$62.5MQuarter to 31 Dec 2024: revenue $7.4M, net income -$70.8MQuarter to 31 Dec 2024: revenue $7.4M, net income -$70.8MQuarter to 31 Mar 2025: revenue $22.1M, net income -$65.6MQuarter to 31 Mar 2025: revenue $22.1M, net income -$65.6MQuarter to 30 Jun 2025: revenue $11.5M, net income -$76.6MQuarter to 30 Jun 2025: revenue $11.5M, net income -$76.6MQuarter to 30 Sep 2025: revenue $2.8M, net income -$82.2MQuarter to 30 Sep 2025: revenue $2.8M, net income -$82.2MQuarter to 31 Dec 2025: revenue $2.9M, net income -$87.0MQuarter to 31 Dec 2025: revenue $2.9M, net income -$87.0MQuarter to 31 Mar 2026: revenue $34.4M, net income -$69.2MQuarter to 31 Mar 2026: revenue $34.4M, net income -$69.2MQuarter to 30 Jun 2026: revenue $65.0M, net income -$61.2MQuarter to 30 Jun 2026: revenue $65.0M, net income -$61.2MQuarter to 30 Sep 2026: revenue $0, net income -$132.0MQuarter to 30 Sep 2026: revenue $0, net income -$132.0M
31 Dec 2021RevenueNet incomeNet losstallest bar $132.0M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$0-$132.0M
30 Jun 2026$65.0M-$61.2M
31 Mar 2026$34.4M-$69.2M
31 Dec 2025$2.9M-$87.0M
30 Sep 2025$2.8M-$82.2M
30 Jun 2025$11.5M-$76.6M
31 Mar 2025$22.1M-$65.6M
31 Dec 2024$7.4M-$70.8M
30 Sep 2024$3.7M-$62.5M
30 Jun 2024$25.6M-$42.1M
31 Mar 2024$10.3M-$48.6M
31 Dec 2023–-$14.4M
30 Sep 2023$4.7M-$52.9M
30 Jun 2023$16.5M-$38.8M
31 Mar 2023$9.5M-$40.9M
31 Dec 2022$16.1M-$34.9M
30 Sep 2022$9.6M-$43.0M
30 Jun 2022$11.5M-$40.3M
31 Mar 2022$9.6M-$36.7M
31 Dec 2021$15.3M-$33.9M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $102.2M $43.7M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +134% +8.2%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$349.4M -$295.1M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$3.63 -$3.60
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 0.0% 0.0% 70.4%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -396% -760% -98.6%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -342% -675% -47.8%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -27.3% -58.2%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. -$288.9M -$230.2M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $971.2M $505.7M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. – –
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). – –
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. – 0.0
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $18.91
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 21.6
P/SPrice to sales: market cap divided by revenue of the last 12 months. 96.3 8.0
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. – 6.0
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 6.1 2.0

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
Kymera TherapeuticsKYMR (this company) $9.8Bloss96.3+134%-342%
Halozyme TherapeuticsHALO $10.4B21.55.8+45%26.9%
RepligenRGEN $10.5Bloss13.0+14%-1.5%
Krystal BiotechKRYS $9.2B40.719.5+26%47.9%
VaxcytePCVX $8.8Bloss–––
Bio-TechneTECH $11.4B66.49.3+0.9%14.0%

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$4.2M

bought $0, sold $4.2M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+10%

299 13F filers vs 271

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

98.9M shares held by 13F filers (30 Sep 2026) of 85.4M outstanding (23 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

9.8%

8.4M shares sold short (30 Oct 2026) of 85.4M outstanding (23 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

10.5

8.4M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-8.4%

9.2M shares sold short in the report before, 8.4M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

42%

42% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 69%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

21

Tracked since 20 Nov 2026

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

Tracking started 20 Nov 2026; the change shows after 30 days.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

–

No data for this company

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

–

No data for this company

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

–

No data for this company

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

36

36 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

12×

36 articles in the last 7 days; its usual week has 3.

Price $115.31 on 20 Nov 2026, +78% over 12 months (12-month range $64.27 to $138.86)

  • Sharp change
  • 8-K and other filings
Insider net buying (open market). Insiders sold a net $292.5M in the last 12 months (the 12 months before: $27.8M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 5 published in the last 12 months, 0% on the 12 months before.
Revenue per quarter. Revenue $0 in the latest quarter, -100% on a year earlier.
Capital spending per quarter. Capital spending $315K in the latest quarter, +74% on a year earlier.
Institutional holders (13F filers). 299 13F filers reported holding it in the latest 13F quarter, +47% on a year earlier.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, lobbying spend, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
6 Aug 2026Sharp changeQuarterly revenue change: quarterly revenue change, 65.0M vs usual 9.4M (2026-06-30); 5.7x the same period a year earlier
27 Jul 20268-K and other filingsDirector or officer change
8 Jun 20268-K and other filingsDirector or officer change
8 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
5 May 2026Sharp changeQuarterly revenue change: quarterly revenue change, 34.4M vs usual 8.8M (2026-03-31); 1.6x the same period a year earlier
26 Feb 20268-K and other filingsA major agreement ended
3 Sep 20258-K and other filingsDirector or officer change
3 Sep 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Aug 2025Sharp changeMany funds opening a new position: many funds opening a new position, 64 vs usual 22 (2025-06-30); 2.9x the same period a year earlier
3 Mar 20258-K and other filingsDirector or officer change
27 Feb 20258-K and other filingsDirector or officer change
27 Feb 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
13 Aug 2024Sharp changeQuarterly revenue change: quarterly revenue change, 25.6M vs usual 10.0M (2024-06-30); 1.6x the same period a year earlier
20 Jun 20248-K and other filingsDirector or officer change
21 May 2024Sharp changeMany funds opening a new position: many funds opening a new position, 38 vs usual 13.50 (2024-03-31); 2.9x the same period a year earlier
1 Apr 20248-K and other filingsDirector or officer change
1 Apr 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
27 Feb 2024Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 11.6M vs usual 990K (2023-12-31); 31.2x the same period a year earlier
20 Feb 2024Sharp changeMany funds opening a new position: many funds opening a new position, 26 vs usual 13.50 (2023-12-31); 2.0x the same period a year earlier
7 Nov 2023Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 8.1M vs usual 618K (2023-09-30); 6.5x the same period a year earlier
8 Aug 2023Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 10.8M vs usual 564K (2023-06-30); 14.7x the same period a year earlier
22 May 20238-K and other filingsDirector or officer change
27 Feb 20238-K and other filingsDirector or officer change
27 Feb 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Nov 20228-K and other filingsDirector or officer change
3 Nov 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
16 Aug 2022Sharp changeShort interest spike: short interest spike, 6.1M vs usual 2.2M (2022-07-29); 3.0x the same period a year earlier
2 Aug 2022Sharp changeShort interest spike: short interest spike, 6.4M vs usual 2.2M (2022-07-15); 3.3x the same period a year earlier
19 Jul 2022Sharp changeShort interest spike: short interest spike, 5.8M vs usual 2.1M (2022-06-30); 2.5x the same period a year earlier
8 Jul 20228-K and other filingsDirector or officer change
28 Jun 2022Sharp changeShort interest spike: short interest spike, 5.0M vs usual 2.0M (2022-06-15); 2.8x the same period a year earlier
14 Jun 2022Sharp changeShort interest spike: short interest spike, 4.9M vs usual 2.0M (2022-05-31); 2.5x the same period a year earlier
31 May 2022Sharp changeShort interest spike: short interest spike, 4.9M vs usual 2.0M (2022-05-13); 2.3x the same period a year earlier
11 Apr 20228-K and other filingsDirector or officer change
18 Jan 20228-K and other filingsDirector or officer change
18 Jan 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
Insider net buying (open market)
Month from 1 Dec 2021: -$536K published
Month from 1 Jan 2022: $7.0M published
Month from 1 Feb 2022: $5.1M published
Month from 1 May 2022: $5.0M published
Month from 1 Jun 2022: $4.2M published
Month from 1 Aug 2022: $14.2M published
Month from 1 Nov 2022: -$27.3M published
Month from 1 Dec 2022: -$21.4M published
Month from 1 Jan 2023: -$5.6M published
Month from 1 Mar 2023: -$105K published
Month from 1 Nov 2023: $5.3M published
Month from 1 Jan 2024: -$375K published
Month from 1 Feb 2024: -$1.8M published
Month from 1 Mar 2024: -$32.7M published
Month from 1 May 2024: -$90K published
Month from 1 Jun 2024: -$1.2M published
Month from 1 Jul 2024: -$19.2M published
Month from 1 Aug 2024: -$245K published
Month from 1 Sep 2024: -$652K published
Month from 1 Dec 2024: -$122K published
Month from 1 Jan 2025: -$131K published
Month from 1 Mar 2025: -$499K published
Month from 1 May 2025: -$75K published
Month from 1 Jun 2025: -$2.8M published
Month from 1 Jul 2025: $42.8M published
Month from 1 Sep 2025: -$5.4M published
Month from 1 Oct 2025: -$6.0M published
Month from 1 Dec 2025: $134.8M published
Month from 1 Jan 2026: -$2.7M published
Month from 1 Feb 2026: -$2.9M published
Month from 1 Mar 2026: -$21.3M published
Month from 1 Apr 2026: -$8.4M published
Month from 1 May 2026: -$1.6M published
Month from 1 Jun 2026: -$301.9M published
Month from 1 Jul 2026: -$84.3M published
Month from 1 Sep 2026: -$744K published
Month from 1 Oct 2026: -$3.4M published
H-1B/E-3 applications certified
Quarter from 1 Jul 2022: 3 published
Quarter from 1 Jan 2023: 1 published
Quarter from 1 Jul 2023: 2 published
Quarter from 1 Oct 2023: 1 published
Quarter from 1 Jan 2024: 1 published
Quarter from 1 Jul 2024: 1 published
Quarter from 1 Apr 2025: 1 published
Quarter from 1 Jul 2025: 1 published
Quarter from 1 Oct 2025: 3 published
Quarter from 1 Apr 2026: 1 published
Quarter from 1 Jul 2026: 2 published
Quarter from 1 Oct 2026: 2 published
Revenue per quarter
Quarter ended 31 Dec 2021: $15.3M, +19% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $9.6M, -49% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $11.5M, -38% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $9.6M, -53% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $16.1M, +5.7% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $9.5M, -1.6% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $16.5M, +43% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $4.7M, -50% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Mar 2024: $10.3M, +8.7% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $25.6M, +55% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $3.7M, -21% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $7.4M; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $22.1M, +115% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $11.5M, -55% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $2.8M, -26% on a year earlier; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $2.9M, -61% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $34.4M, +55% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $65.0M, +466% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $0, -100% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $501K, -65% on a year earlier; public on 25 Feb 2022
Quarter ended 31 Mar 2022: $482K, +194% on a year earlier; public on 4 May 2022
Quarter ended 30 Jun 2022: $735K, +17% on a year earlier; public on 10 Aug 2022
Quarter ended 30 Sep 2022: $1.2M, +307% on a year earlier; public on 4 Nov 2022
Quarter ended 31 Dec 2022: $373K, -26% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $4.0M, +732% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $10.8M, +1365% on a year earlier; public on 4 Aug 2023
Quarter ended 30 Sep 2023: $8.1M, +548% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $11.6M, +3017% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $7.4M, +85% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $4.7M, -56% on a year earlier; public on 8 Aug 2024
Quarter ended 31 Dec 2024: $936K, -92% on a year earlier; public on 28 Feb 2025
Quarter ended 31 Mar 2025: $467K, -94% on a year earlier; public on 10 May 2025
Quarter ended 30 Jun 2025: $695K, -85% on a year earlier; public on 12 Aug 2025
Quarter ended 30 Sep 2025: $181K; public on 5 Nov 2025
Quarter ended 31 Dec 2025: $106K, -89% on a year earlier; public on 27 Feb 2026
Quarter ended 31 Mar 2026: $434K, -7.1% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $473K, -32% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $315K, +74% on a year earlier; public on 30 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 116; public on 14 Feb 2022
31 Mar 2022 report: 119; public on 16 May 2022
30 Jun 2022 report: 96; public on 15 Aug 2022
30 Sep 2022 report: 115; public on 14 Nov 2022
31 Dec 2022 report: 109; public on 14 Feb 2023
31 Mar 2023 report: 121; public on 15 May 2023
30 Jun 2023 report: 121; public on 14 Aug 2023
30 Sep 2023 report: 111; public on 14 Nov 2023
31 Dec 2023 report: 126; public on 14 Feb 2024
31 Mar 2024 report: 155; public on 15 May 2024
30 Jun 2024 report: 148; public on 14 Aug 2024
30 Sep 2024 report: 172; public on 14 Nov 2024
31 Dec 2024 report: 176; public on 14 Feb 2025
31 Mar 2025 report: 167; public on 15 May 2025
30 Jun 2025 report: 204; public on 14 Aug 2025
30 Sep 2025 report: 204; public on 14 Nov 2025
31 Dec 2025 report: 247; public on 17 Feb 2026
31 Mar 2026 report: 251; public on 15 May 2026
30 Jun 2026 report: 271; public on 14 Aug 2026
30 Sep 2026 report: 299; public on 16 Nov 2026

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is research and development expense, quarter at $128.5M (30 Sep 2026), 1.8× its normal quarter; higher than 100% of its own history.
  • Quarterly revenue change: reported revenue of $65.0M for the quarter ended 30 Jun 2026, 5.7× the same quarter last year Public on 6 Aug 2026.
  • Insider net buying (open market): Insiders sold a net $292.5M in the last 12 months (the 12 months before: $27.8M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 5 published in the last 12 months, 0% on the 12 months before.

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 2 sales, $4.2M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
1 Oct 2026Nello MainolfiChief Executive OfficerSellplanned in advance (10b5-1); after exercising options30,000$113.80$3.4MForm 4
4 Sep 2026Brian AdamsChief Legal OfficerSell6,371$116.83$744KForm 4
7 Jul 2026Nello MainolfiChief Executive OfficerSellplanned in advance (10b5-1); after exercising options50,000$119.00$6.0MForm 4
2 Jul 2026Noah GoodmanChief Business OfficerSellplanned in advance (10b5-1)3,389$114.29$387KForm 4
2 Jul 2026Bruce N. JacobsChief Financial OfficerSellplanned in advance (10b5-1); after exercising options77,109$114.97$8.9MForm 4
2 Jul 2026Nello MainolfiChief Executive OfficerSellplanned in advance (10b5-1); after exercising options80,000$115.30$9.2MForm 4
30 Jun 2026Bruce BoothDirectorSellplanned in advance (10b5-1)31,283$109.48$3.4MForm 4
30 Jun 2026Bruce BoothDirectorSellplanned in advance (10b5-1)513,245$110.01$56.5MForm 4

299 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 48 opened a position, 21 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
FMR LLC (Fidelity)12.6M14.7%$1.4B+220K+1.8%
T. Rowe Price Associates Inc8.7M10.2%+1.6M+23%
Baker Bros. Advisors LP8.7M10.1%$967.8MNo change
Avoro Capital Advisors LLC7.5M8.76%$835.6MNo change
BlackRock, Inc.5.8M6.82%$651.2M+287K+5.2%
T. Rowe Price Investment Management, Inc.5.7M6.72%-521K-8.3%
BVF Inc3.9M4.54%$432.9MNo change
Wellington Management Group LLP3.7M4.34%$414.4M+32K+0.9%
Vanguard Capital Management LLC3.0M3.57%$340.3M+112K+3.8%
Vanguard Portfolio Management LLC3.0M3.49%$333.0M-14K-0.5%

Company events

All 30 company events

In 12 months: 2 major agreements, 2 director or officer changes, 1 agreement ended. Results releases and routine reports are left out.

FiledWhat happenedSource
27 Jul 2026Director or officer change8-K
8 Jun 2026Director or officer change8-K
26 Feb 2026Signed a major agreement; A major agreement ended8-K
10 Dec 2025Signed a major agreement8-K
3 Sep 2025Director or officer change8-K
27 Jun 2025Signed a major agreement8-K
3 Mar 2025Director or officer change8-K
27 Feb 2025Director or officer change8-K

21 open postings; careers site tracked since 20 Nov 2026. Most in Operations & administration 24%, Program & project management 19%, Legal, policy & compliance 10%, ML / AI 10%.

PostedJobLocation
18 Nov 2026Lab Operations CoordinatorOperations & administrationWatertown, MA
9 Oct 2026Associate Director or Director, Statistical ProgrammingProgram & project managementWatertown, MA
8 Sep 2026Senior Clinical Trial AssociateWatertown, MA
8 Sep 2026Sr. Manager or Associate Director or Director, BiostatisticsLegal, policy & complianceWatertown, MA
28 Aug 2026Associate Director or Director, Clinical ScientistResearch & scienceWatertown, MA
21 Aug 2026Director or Senior Director, Program ManagementProgram & project managementWatertown, MA
19 Aug 2026Director or Senior Director, CMC Program ManagementProgram & project managementWatertown, MA
19 Aug 2026Associate Director, Analytical DevelopmentTest, quality & reliabilityWatertown, MA

The 5 newest of 183 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

27 Feb 2024confirmed

Confirmed across sources Institutional holdings and Filings + Financials

Kymera Therapeutics (KYMR): saw 26 13F filers open a new position in the quarter ended 31 Dec 2023, 2.0× the same quarter last year, while it spent $11.6M on capital projects in the quarter ended 31 Dec 2023, 31× the same quarter last year. Two unrelated kinds of activity within 7 days.

  • Institutional holdings: Many funds opening a new position, became public on 14 Feb 2024
  • Financials: Quarterly capital spending jump, became public on 27 Feb 2024
2021-12-31: 192022-03-31: 142022-06-30: 122022-09-30: 292022-12-31: 132023-03-31: 132023-06-30: 172023-09-30: 112023-12-31: 26
The quarter ended 31 Dec 2023 against the 8 quarters before it. this quarterearliernormal: 13.5
See the evidence (2 changes)

Institutional holdings: Many funds opening a new position became public on 14 Feb 2024

Kymera Therapeutics saw 26 13F filers open a new position in the quarter ended 31 Dec 2023, 2.0× the same quarter last year.

This period
26 (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
13.5
Typical spread (median absolute deviation)
2
How far from its usual level
+4.2
Same quarter last year
13
History used
1,187 days
2021-12-31: 192022-03-31: 142022-06-30: 122022-09-30: 292022-12-31: 132023-03-31: 132023-06-30: 172023-09-30: 112023-12-31: 26
the quarter ended 31 Dec 20238 earlier quartersnormal: 13.5

Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

Check it at the source: SEC Form 13F data sets.

Financials: Quarterly capital spending jump became public on 27 Feb 2024

Kymera Therapeutics spent $11.6M on capital projects in the quarter ended 31 Dec 2023, 31× the same quarter last year.

This period
$11.6M (the quarter ended 31 Dec 2023)
Normal quarter (median of 8 earlier)
$990K
Typical spread (median absolute deviation)
$563K
How far from its usual level
+10.6
Same quarter last year
$373K
History used
1,461 days
2021-12-31: $501K2022-03-31: $482K2022-06-30: $735K2022-09-30: $1.2M2022-12-31: $373K2023-03-31: $4.0M2023-06-30: $10.8M2023-09-30: $8.1M2023-12-31: $11.6M
the quarter ended 31 Dec 20238 earlier quartersnormal: $990K

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 6 Aug 2026Financials change

    reported revenue of $65.0M for the quarter ended 30 Jun 2026, 5.7× the same quarter last year.

    Same quarter last year: $11.5M; its normal quarter is $9.4M.

    See the evidence
    This period
    $65.0M (the quarter ended 30 Jun 2026)
    Normal quarter (median of 8 earlier)
    $9.4M
    Typical spread (median absolute deviation)
    $6.6M
    How far from its usual level
    +5.7
    Same quarter last year
    $11.5M
    History used
    2,465 days
    2024-06-30: $25.6M2024-09-30: $3.7M2024-12-31: $7.4M2025-03-31: $22.1M2025-06-30: $11.5M2025-09-30: $2.8M2025-12-31: $2.9M2026-03-31: $34.4M2026-06-30: $65.0M
    the quarter ended 30 Jun 20268 earlier quartersnormal: $9.4M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  2. 27 Jul 2026Filings record

    Director or officer change

  3. 8 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  4. 8 Jun 2026Filings record

    Director or officer change

  5. 5 May 2026Financials change

    reported revenue of $34.4M for the quarter ended 31 Mar 2026, 1.6× the same quarter last year.

    Same quarter last year: $22.1M; its normal quarter is $8.8M.

    See the evidence
    This period
    $34.4M (the quarter ended 31 Mar 2026)
    Normal quarter (median of 8 earlier)
    $8.8M
    Typical spread (median absolute deviation)
    $5.5M
    How far from its usual level
    +3.1
    Same quarter last year
    $22.1M
    History used
    2,374 days
    2024-03-31: $10.3M2024-06-30: $25.6M2024-09-30: $3.7M2024-12-31: $7.4M2025-03-31: $22.1M2025-06-30: $11.5M2025-09-30: $2.8M2025-12-31: $2.9M2026-03-31: $34.4M
    the quarter ended 31 Mar 20268 earlier quartersnormal: $8.8M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  6. 26 Feb 2026Filings record

    A major agreement ended

  7. 12 Dec 2025Insiders record

    BAKER FELIX (director) and 5 other(s) bought 2,005,813 shares of KYMR ($172.5M) (dated 11 Dec 2025)

  8. 3 Sep 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  9. 3 Sep 2025Filings record

    Director or officer change

  10. 14 Aug 2025Institutional holdings change

    saw 64 13F filers open a new position in the quarter ended 30 Jun 2025, 2.9× the same quarter last year.

    Same quarter last year: 22; its normal quarter is 22.

    See the evidence
    This period
    64 (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    22
    Typical spread (median absolute deviation)
    4.5
    How far from its usual level
    +6.3
    Same quarter last year
    22
    History used
    1,734 days
    2023-06-30: 172023-09-30: 112023-12-31: 262024-03-31: 382024-06-30: 222024-09-30: 322024-12-31: 222025-03-31: 182025-06-30: 64
    the quarter ended 30 Jun 20258 earlier quartersnormal: 22

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  11. 2 Jul 2025Insiders record

    Biotechnology Value Trading Fund OS LP (See Remarks and Footnotes) and 9 other(s) bought 317,167 shares of KYMR ($14.0M) (dated 1 Jul 2025)

  12. 1 Jul 2025Insiders record

    Baker Bros. Advisors (GP) LLC (director) and 5 other(s) bought 655,500 shares of KYMR ($28.8M) (dated 30 Jun 2025)

  13. 3 Mar 2025Filings record

    Director or officer change

  14. 27 Feb 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  15. 27 Feb 2025Filings record

    Director or officer change

  16. 23 Aug 2024Insiders record

    667, L.P. (director) and 5 other(s) bought 1 shares of KYMR ($46) (dated 22 Aug 2024)

  17. 13 Aug 2024Financials change

    reported revenue of $25.6M for the quarter ended 30 Jun 2024, 1.6× the same quarter last year.

    Same quarter last year: $16.5M; its normal quarter is $10.0M.

    See the evidence
    This period
    $25.6M (the quarter ended 30 Jun 2024)
    Normal quarter (median of 8 earlier)
    $10.0M
    Typical spread (median absolute deviation)
    $1.0M
    How far from its usual level
    +10.3
    Same quarter last year
    $16.5M
    History used
    1,735 days
    2022-03-31: $9.6M2022-06-30: $11.5M2022-09-30: $9.6M2022-12-31: $16.1M2023-03-31: $9.5M2023-06-30: $16.5M2023-09-30: $4.7M2024-03-31: $10.3M2024-06-30: $25.6M
    the quarter ended 30 Jun 20248 earlier quartersnormal: $10.0M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  18. 20 Jun 2024Filings record

    Director or officer change

  19. 15 May 2024Institutional holdings change

    saw 38 13F filers open a new position in the quarter ended 31 Mar 2024, 2.9× the same quarter last year.

    Same quarter last year: 13; its normal quarter is 13.5.

    See the evidence
    This period
    38 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    13.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +8.2
    Same quarter last year
    13
    History used
    1,278 days
    2022-03-31: 142022-06-30: 122022-09-30: 292022-12-31: 132023-03-31: 132023-06-30: 172023-09-30: 112023-12-31: 262024-03-31: 38
    the quarter ended 31 Mar 20248 earlier quartersnormal: 13.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  20. 1 Apr 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  21. 1 Apr 2024Filings record

    Director or officer change

  22. 27 Feb 2024several at once

    saw 26 13F filers open a new position in the quarter ended 31 Dec 2023, 2.0× the same quarter last year, while it spent $11.6M on capital projects in the quarter ended 31 Dec 2023, 31× the same quarter last year. Two unrelated kinds of activity within 7 days.

    See the evidence (2 changes)

    Institutional holdings: Many funds opening a new position became public on 14 Feb 2024

    Kymera Therapeutics saw 26 13F filers open a new position in the quarter ended 31 Dec 2023, 2.0× the same quarter last year.

    This period
    26 (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    13.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +4.2
    Same quarter last year
    13
    History used
    1,187 days
    2021-12-31: 192022-03-31: 142022-06-30: 122022-09-30: 292022-12-31: 132023-03-31: 132023-06-30: 172023-09-30: 112023-12-31: 26
    the quarter ended 31 Dec 20238 earlier quartersnormal: 13.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

    Financials: Quarterly capital spending jump became public on 27 Feb 2024

    Kymera Therapeutics spent $11.6M on capital projects in the quarter ended 31 Dec 2023, 31× the same quarter last year.

    This period
    $11.6M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    $990K
    Typical spread (median absolute deviation)
    $563K
    How far from its usual level
    +10.6
    Same quarter last year
    $373K
    History used
    1,461 days
    2021-12-31: $501K2022-03-31: $482K2022-06-30: $735K2022-09-30: $1.2M2022-12-31: $373K2023-03-31: $4.0M2023-06-30: $10.8M2023-09-30: $8.1M2023-12-31: $11.6M
    the quarter ended 31 Dec 20238 earlier quartersnormal: $990K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

    Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

  23. 27 Feb 2024Financials change

    spent $11.6M on capital projects in the quarter ended 31 Dec 2023, 31× the same quarter last year.

    Same quarter last year: $373K; its normal quarter is $990K.

    See the evidence
    This period
    $11.6M (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    $990K
    Typical spread (median absolute deviation)
    $563K
    How far from its usual level
    +10.6
    Same quarter last year
    $373K
    History used
    1,461 days
    2021-12-31: $501K2022-03-31: $482K2022-06-30: $735K2022-09-30: $1.2M2022-12-31: $373K2023-03-31: $4.0M2023-06-30: $10.8M2023-09-30: $8.1M2023-12-31: $11.6M
    the quarter ended 31 Dec 20238 earlier quartersnormal: $990K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  24. 14 Feb 2024Institutional holdings change

    saw 26 13F filers open a new position in the quarter ended 31 Dec 2023, 2.0× the same quarter last year.

    Same quarter last year: 13; its normal quarter is 13.5.

    See the evidence
    This period
    26 (the quarter ended 31 Dec 2023)
    Normal quarter (median of 8 earlier)
    13.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +4.2
    Same quarter last year
    13
    History used
    1,187 days
    2021-12-31: 192022-03-31: 142022-06-30: 122022-09-30: 292022-12-31: 132023-03-31: 132023-06-30: 172023-09-30: 112023-12-31: 26
    the quarter ended 31 Dec 20238 earlier quartersnormal: 13.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  25. 7 Nov 2023Financials change

    spent $8.1M on capital projects in the quarter ended 30 Sep 2023, 6.5× the same quarter last year.

    Same quarter last year: $1.2M; its normal quarter is $618K.

    See the evidence
    This period
    $8.1M (the quarter ended 30 Sep 2023)
    Normal quarter (median of 8 earlier)
    $618K
    Typical spread (median absolute deviation)
    $278K
    How far from its usual level
    +7.5
    Same quarter last year
    $1.2M
    History used
    1,369 days
    2021-09-30: $306K2021-12-31: $501K2022-03-31: $482K2022-06-30: $735K2022-09-30: $1.2M2022-12-31: $373K2023-03-31: $4.0M2023-06-30: $10.8M2023-09-30: $8.1M
    the quarter ended 30 Sep 20238 earlier quartersnormal: $618K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  26. 7 Nov 2023Insiders record

    BVF II GP LLC (See Remarks and Footnotes) and 9 other(s) bought 414,105 shares of KYMR ($5.3M) (dated 6 Nov 2023)

  27. 8 Aug 2023Financials change

    spent $10.8M on capital projects in the quarter ended 30 Jun 2023, 15× the same quarter last year.

    Same quarter last year: $735K; its normal quarter is $564K.

    See the evidence
    This period
    $10.8M (the quarter ended 30 Jun 2023)
    Normal quarter (median of 8 earlier)
    $564K
    Typical spread (median absolute deviation)
    $181K
    How far from its usual level
    +10.2
    Same quarter last year
    $735K
    History used
    1,277 days
    2021-06-30: $626K2021-09-30: $306K2021-12-31: $501K2022-03-31: $482K2022-06-30: $735K2022-09-30: $1.2M2022-12-31: $373K2023-03-31: $4.0M2023-06-30: $10.8M
    the quarter ended 30 Jun 20238 earlier quartersnormal: $564K

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  28. 22 May 2023Filings record

    Director or officer change

  29. 27 Feb 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 27 Feb 2023Filings record

    Director or officer change

  31. 14 Jan 2023Insiders record

    BIOTECHNOLOGY VALUE FUND II LP (See Remarks and Footnotes) and 9 other(s) bought 41,007 shares of KYMR ($1.3M) (dated 13 Jan 2023)

  32. 3 Nov 2022Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  33. 3 Nov 2022Filings record

    Director or officer change

  34. 24 Aug 2022Insiders record

    BIOTECHNOLOGY VALUE FUND II LP (See Remarks and Footnotes) and 9 other(s) bought 545,525 shares of KYMR ($14.2M) (dated 23 Aug 2022)

  35. 10 Aug 2022Short interest and volume change

    had 6.1M shares sold short in the 29 Jul 2022 report, 3.0× the same report last year.

    Same report last year: 2.1M; its normal report is 2.2M.

    See the evidence
    This period
    6.1M (the 29 Jul 2022 report)
    Normal report (median of 24 earlier)
    2.2M
    Typical spread (median absolute deviation)
    669K
    How far from its usual level
    +4.0
    Same report last year
    2.1M
    History used
    697 days
    2021-07-15: 1.9M2021-07-30: 2.1M2021-08-13: 2.0M2021-08-31: 1.7M2021-09-15: 1.5M2021-09-30: 1.6M2021-10-15: 1.4M2021-10-29: 1.4M2021-11-15: 1.5M2021-11-30: 1.7M2021-12-15: 1.7M2022-01-14: 2.0M2022-01-31: 2.3M2022-02-15: 2.6M2022-02-28: 2.8M2022-03-15: 3.1M2022-03-31: 3.0M2022-04-14: 3.3M2022-04-29: 3.5M2022-05-13: 4.9M2022-05-31: 4.9M2022-06-15: 5.0M2022-06-30: 5.8M2022-07-15: 6.4M2022-07-29: 6.1M
    the 29 Jul 2022 report24 earlier reportsnormal: 2.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  36. 27 Jul 2022Short interest and volume change

    had 6.4M shares sold short in the 15 Jul 2022 report, 3.3× the same report last year.

    Same report last year: 1.9M; its normal report is 2.2M.

    See the evidence
    This period
    6.4M (the 15 Jul 2022 report)
    Normal report (median of 24 earlier)
    2.2M
    Typical spread (median absolute deviation)
    651K
    How far from its usual level
    +4.4
    Same report last year
    1.9M
    History used
    683 days
    2021-06-30: 2.4M2021-07-15: 1.9M2021-07-30: 2.1M2021-08-13: 2.0M2021-08-31: 1.7M2021-09-15: 1.5M2021-09-30: 1.6M2021-10-15: 1.4M2021-10-29: 1.4M2021-11-15: 1.5M2021-11-30: 1.7M2021-12-15: 1.7M2022-01-14: 2.0M2022-01-31: 2.3M2022-02-15: 2.6M2022-02-28: 2.8M2022-03-15: 3.1M2022-03-31: 3.0M2022-04-14: 3.3M2022-04-29: 3.5M2022-05-13: 4.9M2022-05-31: 4.9M2022-06-15: 5.0M2022-06-30: 5.8M2022-07-15: 6.4M
    the 15 Jul 2022 report24 earlier reportsnormal: 2.2M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  37. 13 Jul 2022Short interest and volume change

    had 5.8M shares sold short in the 30 Jun 2022 report, 2.5× the same report last year.

    Same report last year: 2.4M; its normal report is 2.1M.

    See the evidence
    This period
    5.8M (the 30 Jun 2022 report)
    Normal report (median of 24 earlier)
    2.1M
    Typical spread (median absolute deviation)
    544K
    How far from its usual level
    +4.7
    Same report last year
    2.4M
    History used
    668 days
    2021-06-15: 1.8M2021-06-30: 2.4M2021-07-15: 1.9M2021-07-30: 2.1M2021-08-13: 2.0M2021-08-31: 1.7M2021-09-15: 1.5M2021-09-30: 1.6M2021-10-15: 1.4M2021-10-29: 1.4M2021-11-15: 1.5M2021-11-30: 1.7M2021-12-15: 1.7M2022-01-14: 2.0M2022-01-31: 2.3M2022-02-15: 2.6M2022-02-28: 2.8M2022-03-15: 3.1M2022-03-31: 3.0M2022-04-14: 3.3M2022-04-29: 3.5M2022-05-13: 4.9M2022-05-31: 4.9M2022-06-15: 5.0M2022-06-30: 5.8M
    the 30 Jun 2022 report24 earlier reportsnormal: 2.1M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  38. 8 Jul 2022Filings record

    Director or officer change

  39. 28 Jun 2022Short interest and volume change

    had 5.0M shares sold short in the 15 Jun 2022 report, 2.8× the same report last year.

    Same report last year: 1.8M; its normal report is 2.0M.

    See the evidence
    This period
    5.0M (the 15 Jun 2022 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    443K
    How far from its usual level
    +4.5
    Same report last year
    1.8M
    History used
    653 days
    2021-05-28: 2.0M2021-06-15: 1.8M2021-06-30: 2.4M2021-07-15: 1.9M2021-07-30: 2.1M2021-08-13: 2.0M2021-08-31: 1.7M2021-09-15: 1.5M2021-09-30: 1.6M2021-10-15: 1.4M2021-10-29: 1.4M2021-11-15: 1.5M2021-11-30: 1.7M2021-12-15: 1.7M2022-01-14: 2.0M2022-01-31: 2.3M2022-02-15: 2.6M2022-02-28: 2.8M2022-03-15: 3.1M2022-03-31: 3.0M2022-04-14: 3.3M2022-04-29: 3.5M2022-05-13: 4.9M2022-05-31: 4.9M2022-06-15: 5.0M
    the 15 Jun 2022 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

  40. 10 Jun 2022Short interest and volume change

    had 4.9M shares sold short in the 31 May 2022 report, 2.5× the same report last year.

    Same report last year: 2.0M; its normal report is 2.0M.

    See the evidence
    This period
    4.9M (the 31 May 2022 report)
    Normal report (median of 24 earlier)
    2.0M
    Typical spread (median absolute deviation)
    359K
    How far from its usual level
    +5.4
    Same report last year
    2.0M
    History used
    638 days
    2021-05-14: 2.1M2021-05-28: 2.0M2021-06-15: 1.8M2021-06-30: 2.4M2021-07-15: 1.9M2021-07-30: 2.1M2021-08-13: 2.0M2021-08-31: 1.7M2021-09-15: 1.5M2021-09-30: 1.6M2021-10-15: 1.4M2021-10-29: 1.4M2021-11-15: 1.5M2021-11-30: 1.7M2021-12-15: 1.7M2022-01-14: 2.0M2022-01-31: 2.3M2022-02-15: 2.6M2022-02-28: 2.8M2022-03-15: 3.1M2022-03-31: 3.0M2022-04-14: 3.3M2022-04-29: 3.5M2022-05-13: 4.9M2022-05-31: 4.9M
    the 31 May 2022 report24 earlier reportsnormal: 2.0M

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.

    Check it at the source: FINRA short interest data.

Showing the newest 40 of 62 entries; narrow the window or the kind of data to see older ones.

Not listed: 200 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001815442
Ticker
KYMR
Domain
kymeratx.com
Employer name
Kymera Therapeutics, Inc. (1 unverified)
Hq location
MA|WATERTOWN|02472 (1 unverified)
Name
ACTIVE/107610297.1, EX-21.1, Kymera Securities Corporation, Kymera Therapeutics, Inc. and 1 more
Wikidata
Q113503520
  • DOL H-1B labor condition applications and PERM certifications96 data points8 Feb 2021 to 27 Jul 2026
  • SEC Form 13F institutional holdings225 data points30 Sep 2020 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)104 records31 Jul 2020 to 29 Oct 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)456 data points31 Dec 2018 to 23 Oct 2026
  • SEC Form 4 insider transactions131 records, 380 data points19 Feb 2021 to 1 Oct 2026
  • FINRA short interest (twice monthly)443 data points31 Aug 2020 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)3142 data points21 Aug 2020 to 20 Nov 2026